- Home
- TPVG vs NTHI Comparison
TPVG vs NTHI Comparison
Compare TPVG & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPVG
- NTHI
- Stock Information
- Founded
- TPVG 2013
- NTHI 2008
- Country
- TPVG United States
- NTHI United States
- Employees
- TPVG N/A
- NTHI N/A
- Industry
- TPVG Other Consumer Services
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- TPVG Consumer Discretionary
- NTHI Health Care
- Exchange
- TPVG Nasdaq
- NTHI Nasdaq
- Market Cap
- TPVG 226.6M
- NTHI 211.9M
- IPO Year
- TPVG N/A
- NTHI N/A
- Fundamental
- Price
- TPVG $5.47
- NTHI $10.67
- Analyst Decision
- TPVG Hold
- NTHI
- Analyst Count
- TPVG 6
- NTHI 0
- Target Price
- TPVG $6.38
- NTHI N/A
- AVG Volume (30 Days)
- TPVG 271.3K
- NTHI 40.6K
- Earning Date
- TPVG 11-05-2025
- NTHI 11-19-2025
- Dividend Yield
- TPVG 16.85%
- NTHI N/A
- EPS Growth
- TPVG N/A
- NTHI N/A
- EPS
- TPVG 1.03
- NTHI N/A
- Revenue
- TPVG $97,395,000.00
- NTHI $59,990.00
- Revenue This Year
- TPVG N/A
- NTHI N/A
- Revenue Next Year
- TPVG $7.69
- NTHI N/A
- P/E Ratio
- TPVG $5.30
- NTHI N/A
- Revenue Growth
- TPVG N/A
- NTHI N/A
- 52 Week Low
- TPVG $5.24
- NTHI $3.20
- 52 Week High
- TPVG $8.50
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- TPVG 38.08
- NTHI N/A
- Support Level
- TPVG $5.38
- NTHI N/A
- Resistance Level
- TPVG $5.59
- NTHI N/A
- Average True Range (ATR)
- TPVG 0.14
- NTHI 0.00
- MACD
- TPVG 0.01
- NTHI 0.00
- Stochastic Oscillator
- TPVG 13.05
- NTHI 0.00
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).